Phase Changes in the BRCA Policy Domain

Journal of Religion and Health

Volumn 53, Issue 3, 2014, Pages 715-724

  Modell, Stephen M ^a   King, Susan B ^a   Citrin, Toby ^a   Kardia, Sharon L R ^a  

^a UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Accessibility; Breast cancer; Cost; Ethics; Gene patents; Predictive genetic tests; Religious policy

Indexed keywords

EID: 84899413875     PISSN: 00224197     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10943-014-9836-0     Document Type: Article

References (39)

1. Andre, J. (1992). Blocked exchanges: A taxonomy. Ethics, 103(1), 29-47.
2. Armstrong, K., Micco, E., Carney, A., Stopfer, J., & Putt, M. (2005). Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer. Journal of the American Medical Association, 293(14), 1729-1736.
3. Atwood, K., Colditz, G. A., & Kawachi, I. (1997). From public health science to prevention policy: Placing science in its social and political contexts. American Journal of Public Health, 87(10), 1603-1606.
4. Brandt-Rauf, S. I., Raveis, V. H., Drummond, N. F., Conte, J. A., & Rothman, S. M. (2006). Ashkenazi Jews and breast cancer: The consequences of linking ethnic identity to genetic disease. American Journal of Public Health, 96(11), 1979-1988.
5. Branson, H. (1992). Keynote address: Africa, African-Americans, and the origin of a universal ethic. In H. E. Flack & E. D. Pellegrino (Eds.), African-American perspectives on biomedical ethics (pp. 1-10). Washington, D. C.: Georgetown University Press.
6. Caplan, A. L., & Merz, J. (1996). Patenting gene sequences. BMJ, 312(7036), 926.
7. Caulfield, T., Cook-Deegan, R. M., Kieff, F. S., & Walsh, J. P. (2006). Evidence and anecdotes: An analysis of human gene patenting controversies. Nature Biotechnology, 24(9), 1091-1094.
8. Cheon, J., Baldwin, L., Maxson, K., Heaney, C., & Cook-Deegan, R. (2013). BRCA briefing page. Durham, NC: Duke Institute for Genome Sciences and Policy, Center for Genome Ethics, Law and Policy. http://genomicsforum. org/files/geno_report_WEB_w_RFI_112revv. pdf. Accessed 25 Dec 2013.
9. Cole-Turner, R. (1995). Religion and gene patenting. Science, 270(5233), 52.
10. Deane-Drummond, C. (2006). Genetic testing and screening. Genetics and Christian ethics (pp. 76-100). New York: Cambridge University Press.
11. Doyle, D. L. (2009). Genetic service delivery: The current system and its strengths and challenges. In: Institute of Medicine. Institute of Medicine roundtable on translating genomic-based research for health. Innovations in service delivery in the Age of Genomics: Workshop summary. (pp. 3-20). Washington, DC: The National Academies Press.
12. Eisenberg, D. (2007). Genetic screening for breast cancer genes. Jerusalem: Aish. com. http://www. aish. com/ci/sam/Genetic_Screening_for_Breast_Cancer_Genes. html. Accessed 16 Dec 2013.
13. Facing Our Risk of Cancer Empowered (FORCE). (2013). Patient Protection and Affordable Care Act (PPACA): Coverage for genetic counseling and testing. Tampa, FL. http://www. facingourrisk. org/info_research/finding-health-care/financial-help/index. php. Accessed 21 Jan 2014.
14. Ferla, R., Calo, V., Cascio, S., Rinaldi, G., Badalamentil, G., Carreca, I., et al. (2007). Founder mutations in BRCA1 and BRCA2 genes. Annals of Oncology, 18, vi93-vi98.
15. Gold, E. R., & Carbone, J. (2010). Myriad Genetics: In the eye of the storm. Genetics in Medicine, 12(4 Suppl), S39-S70.
16. Hanson, M. J. (2001). Religious voices in biotechnology: The case of gene patenting. In: Claiming power over life: Religion and biotechnology policy. (pp. 72-111). Washington, DC: Georgetown University Press.
17. Hanson, M. J. (2002). Patenting genes and life: Improper commodification? In D. Magnus, A. Caplan, & G. McGee (Eds.), Who owns life? (pp. 161-174). Amherst, NY: Prometheus Books.
18. Healthy People 2020 (HP2020). Genomics. Washington, DC: US Department of Health and Human Services. http://www. healthypeople. gov/2020/topicsobjectives2020/overview. aspx?topicid=15. Accessed 1 Jun 2012.
19. Heller, M. A., & Eisenberg, R. S. (1998). Can patents deter innovation? The anticommons in biomedical research. Science, 280(5364), 698-701.
20. Huang, Y.-H. (2013). Gene patents: A broken incentives system. Journal of Religion and Health, 52(4), 1079-1084. doi: 10. 1007/s10943-013-9758-2.
21. Liptak, A. (2013). Justices, 9-0, bar patenting human genes. New York Times, 14 Jun 2013, A1, A16.
22. Marchione, M. (2013). BRCA1 and BRCA2: Court ruling against gene patents may open breast cancer tests to more women. Huffington Post, Jun 14, 2013. http://www. huffingtonpost. ca/2013/06/13/brca1-and-brca2_n_3436607. html. Accessed 14 Jun 2013.
23. Milbank, D. (2013). Justices simplify science with lab bats. Washington Post, 16 Apr 2013, A2.
24. Modell, S. M. (2007). Genetic and reproductive technologies in the light of religious dialogue. Zygon: Journal of Religion and Science, 42(1), 163-182.
25. Modell, S. M., Citrin, T., King, S. B., & Kardia, S. L. R. (2014). The role of religious values in decisions about genetics and the public's health. Journal of Religion and Health doi: 10. 1007/s10943-013-9814-y.
26. Modell, S. M., King, S. B., & Platt, J. E. (2008). Parallel tracks in two faith-based genetic dialogue groups in the state of Michigan: Public health convergences. 136th Annual Meeting of the American Public Health Association, San Diego, CA, 28 Oct 2008. https://apha. confex. com/apha/136am/webprogram/Paper174404. html. Accessed 24 Jan 2014.
27. Mor, P., & Oberle, K. (2008). Ethical issues related to BRCA gene testing in Orthodox Jewish women. Nursing Ethics, 15(4), 512-522.
28. National Council of Churches USA (NCC). (2006). Fearfully and wonderfully made: A policy on human biotechnologies. Washington, DC: National Council of the Churches of Christ in the USA. http://www. ncccusa. org/pdfs/BioTechPolicy. pdf. Accessed 24 Jan 2014.
29. Nelson, J. R. (1994). Official religious positions. In: On the new frontiers of genetics and religion. (pp. 171-205). Grand Rapids, MI: William B. Eerdmans Publishing Company.
30. Parthasarathy, S. (2014). Co-producing knowledge and political legitimacy: Comparing life form patent controversies in Europe and the United States. In R. Hagendijk, S. Hilgartner, & C. Miller (Eds.), Science and democracy: Emerging trends. New York: Routledge.
31. Prouser, N. (2000). Case report: Genetic susceptibility testing for breast and ovarian cancer: A patient's perspective. Journal of Genetic Counseling, 9(2), 153-159.
32. Rabin, R. C. (2013). In Israel, a push to screen for cancer gene leaves many conflicted. New York Times, 27 Nov 2013, A1, A10.
33. Resnik, D. B. (2001). DNA patents and human dignity. Journal of Law, Medicine & Ethics, 29(2), 152-165.
34. Rosenfeld, J., & Mason, C. E. (2013). Pervasive sequence patents cover the entire human genome. Genome Medicine, 5(3), 27.
35. Rosner, F. (1991). Modern medicine and Jewish ethics (2nd ed.). New York, NY: Yeshiva University Press.
36. Suther, S., & Kiros, G. E. (2009). Barriers to the use of genetic testing: a study of racial and ethnic disparities. Genetics in Medicine, 11(9), 655-662.
37. US Department of Health and Human Services (U. S. HHS). (2013). Preventive services covered under the Affordable Care Act. Washington, DC: US Department of Health and Human Services. http://www. hhs. gov/healthcare/facts/factsheets/2010/07/preventive-services-list. html#PAGE_4. Accessed 29 Jan 2014.
38. US Preventive Services Task Force (USPSTF). (2005). Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: Recommendation statement. Annals of Internal Medicine, 143(5), 355-361.
39. Wooten, M. D. (2012). Distributive justice and Christian health care ethics: A proposed model based on a review of the literature. In A. M. Curtis & D. P. Werthel (Eds.), Religion and healthcare (pp. 1-12). Hauppauge, NY: Nova Science Publishers.